New Company
INHIBITOR Therapeutics Inc.
New Position
Member, board of directors
New Company Website
Former Company
Former Position
INHIBITOR Therapeutics, Inc. (OTCQB: INTI), a Tampa biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to inhibit the progression of cancerous and non-cancerous proliferation disorders, today announced that Debra Peattie, PhD, MBA has been appointed as an independent member of its Board of Directors.
Dr. Peattie is a veteran life science entrepreneur who previously served as Senior Director in the Future Pipelines Discovery Division of GlaxoSmithKline, where she focused on translating early-stage science into novel therapeutics within GSK's Discovery Partnerships with Academia initiative. Prior to GSK, Dr. Peattie worked in the Office of Technology Development at Harvard University and in Strategy & Planning at Cubist Pharmaceuticals. Before joining Cubist, she provided business development and scientific advice to established and emerging life science companies through her consulting firm Pleiades Advisors. Dr. Peattie co-founded and served as Chief Scientific Officer of Valeo Medical, Inc., where she directed all operations and was instrumental in fund raising and licensing activities. She also served as a founding scientist for Vertex Pharmaceuticals and was a founding member of the asset management division at MPM Capital, helping to raise and manage the $230 million MPM BioVentures I family of funds.
"We are very excited to welcome Dr. Peattie to INTI's Board of Directors," said W. Mark Watson, INTI's Chairman of the Board. "We expect to take full advantage of Dr. Peattie's scientific, regulatory, business and industry expertise in the field of biopharmaceuticals, and we will look to her to assist INTI's board and management team in pursuit of our corporate and product development goals. We also welcome her input regarding INTI's funding strategies and the potential acquisition or in-license of new technologies to expand our intellectual property and product portfolios."
Dr. Peattie holds an MBA from Harvard Business School and a PhD in Biochemistry & Molecular Biology from Harvard University, where she studied in the laboratory of Walter Gilbert, PhD, Nobel Laureate in Chemistry. She was also a post-doctoral fellow at Stanford University. Dr. Peattie has published extensively in peer-reviewed journals and previously served on multiple biotechnology company boards, including Epiphany Biosciences, InfiMed Therapeutics, Sedecim Therapeutics, t Breeders and Valeo Medical. Dr Peattie currently holds board positions within Harvard Business School and the Faculty of Arts and Sciences at Harvard University as well as with GRO Biosciences, a Harvard Life Lab company using innovative technologies to develop best-in-class protein therapeutics with enhanced properties.
